普拉格雷 (Chinese Wikipedia)

Analysis of information sources in references of the Wikipedia article "普拉格雷" in Chinese language version.

refsWebsite

Global rank Chinese rank

9nih.gov

4^th place

5^th place

9doi.org

2^nd place

23^rd place

3web.archive.org

1^st place

1europa.eu

68^th place

209^th place

1archive.org

6^th place

4^th place

1fda.gov

447^th place

581^st place

1lilly.com

low place

archive.org

Wiviott, Stephen D.; Braunwald, Eugene; McCabe, Carolyn H.; Montalescot, Gilles; Ruzyllo, Witold; Gottlieb, Shmuel; Neumann, Franz-Joseph; Ardissino, Diego; De Servi, Stefano. Prasugrel versus Clopidogrel in Patients with Acute Coronary Syndromes. New England Journal of Medicine. 15 November 2007, 357 (20): 2001–2015. PMID 17982182. doi:10.1056/NEJMoa0706482.

doi.org

Role of prasugrel, a novel P2Y(12) receptor antagonist, in the management of acute coronary syndromes. American Journal of Cardiovascular Drugs. 2009, 9 (4): 213–29. PMID 19655817. doi:10.2165/1131209-000000000-00000.
Wiviott, Stephen D.; Braunwald, Eugene; McCabe, Carolyn H.; Montalescot, Gilles; Ruzyllo, Witold; Gottlieb, Shmuel; Neumann, Franz-Joseph; Ardissino, Diego; De Servi, Stefano. Prasugrel versus Clopidogrel in Patients with Acute Coronary Syndromes. New England Journal of Medicine. 15 November 2007, 357 (20): 2001–2015. PMID 17982182. doi:10.1056/NEJMoa0706482.
Chew, Derek P; Scott, Ian A; Cullen, Louise; French, John K; Briffa, Tom G; Tideman, Philip A; Woodruffe, Stephen; Kerr, Alistair; Branagan, Maree. National Heart Foundation of Australia and Cardiac Society of Australia and New Zealand: Australian clinical guidelines for the management of acute coronary syndromes 2016. Medical Journal of Australia. August 2016, 205 (3): 128–133. PMID 27465769. doi:10.5694/mja16.00368.
Bellemain-Appaix, A.; Kerneis, M.; O'Connor, S. A.; Silvain, J.; Cucherat, M.; Beygui, F.; Barthelemy, O.; Collet, J.-P.; Jacq, L. Reappraisal of thienopyridine pretreatment in patients with non-ST elevation acute coronary syndrome: a systematic review and meta-analysis. BMJ. 24 October 2014, 347 (aug06 2): g6269. PMC 4208629 . PMID 25954988. doi:10.1136/bmj.g6269.
Montalescot, Gilles; Bolognese, Leonardo; Dudek, Dariusz; Goldstein, Patrick; Hamm, Christian; Tanguay, Jean-Francois; ten Berg, Jurrien M.; Miller, Debra L.; Costigan, Timothy M. Pretreatment with Prasugrel in Non–ST-Segment Elevation Acute Coronary Syndromes. New England Journal of Medicine. 12 September 2013, 369 (11): 999–1010. PMID 23991622. doi:10.1056/NEJMoa1308075.
Current oral antiplatelets: focus update on prasugrel. Journal of the American Board of Family Medicine. 2012, 25 (3): 343–9. PMID 22570398. doi:10.3122/jabfm.2012.03.100270.
PPIs Are Not Responsible for Elevating Cardiovascular Risk in Patients on Clopidogrel-A Systematic Review and Meta-Analysis. Frontiers in Physiology. 2018-11-19, 9: 1550. PMC 6252380 . PMID 30510515. doi:10.3389/fphys.2018.01550.
Pharmacodynamic effect and clinical efficacy of clopidogrel and prasugrel with or without a proton-pump inhibitor: an analysis of two randomised trials. Lancet. September 2009, 374 (9694): 989–997. PMID 19726078. doi:10.1016/S0140-6736(09)61525-7.
Efficacy and Safety of Proton-Pump Inhibitors in High-Risk Cardiovascular Subsets of the COGENT Trial. The American Journal of Medicine. September 2016, 129 (9): 1002–5. PMID 27143321. doi:10.1016/j.amjmed.2016.03.042.

europa.eu

ema.europa.eu

European Public Assessment Report for Efient (PDF). EMA. 2009 [2020-09-20]. （原始内容存档 (PDF)于2018-03-19）.

fda.gov

Effient (prasugrel hydrochloride) Prescribing Information. FDA. September 2011 [2020-09-20]. （原始内容存档于2017-01-18）.

lilly.com

pi.lilly.com

Efient: Highlights of prescribing information (PDF). [2020-09-20]. （原始内容存档 (PDF)于2019-07-10）.

nih.gov

ncbi.nlm.nih.gov

Role of prasugrel, a novel P2Y(12) receptor antagonist, in the management of acute coronary syndromes. American Journal of Cardiovascular Drugs. 2009, 9 (4): 213–29. PMID 19655817. doi:10.2165/1131209-000000000-00000.
Wiviott, Stephen D.; Braunwald, Eugene; McCabe, Carolyn H.; Montalescot, Gilles; Ruzyllo, Witold; Gottlieb, Shmuel; Neumann, Franz-Joseph; Ardissino, Diego; De Servi, Stefano. Prasugrel versus Clopidogrel in Patients with Acute Coronary Syndromes. New England Journal of Medicine. 15 November 2007, 357 (20): 2001–2015. PMID 17982182. doi:10.1056/NEJMoa0706482.
Chew, Derek P; Scott, Ian A; Cullen, Louise; French, John K; Briffa, Tom G; Tideman, Philip A; Woodruffe, Stephen; Kerr, Alistair; Branagan, Maree. National Heart Foundation of Australia and Cardiac Society of Australia and New Zealand: Australian clinical guidelines for the management of acute coronary syndromes 2016. Medical Journal of Australia. August 2016, 205 (3): 128–133. PMID 27465769. doi:10.5694/mja16.00368.
Bellemain-Appaix, A.; Kerneis, M.; O'Connor, S. A.; Silvain, J.; Cucherat, M.; Beygui, F.; Barthelemy, O.; Collet, J.-P.; Jacq, L. Reappraisal of thienopyridine pretreatment in patients with non-ST elevation acute coronary syndrome: a systematic review and meta-analysis. BMJ. 24 October 2014, 347 (aug06 2): g6269. PMC 4208629 . PMID 25954988. doi:10.1136/bmj.g6269.
Montalescot, Gilles; Bolognese, Leonardo; Dudek, Dariusz; Goldstein, Patrick; Hamm, Christian; Tanguay, Jean-Francois; ten Berg, Jurrien M.; Miller, Debra L.; Costigan, Timothy M. Pretreatment with Prasugrel in Non–ST-Segment Elevation Acute Coronary Syndromes. New England Journal of Medicine. 12 September 2013, 369 (11): 999–1010. PMID 23991622. doi:10.1056/NEJMoa1308075.
Current oral antiplatelets: focus update on prasugrel. Journal of the American Board of Family Medicine. 2012, 25 (3): 343–9. PMID 22570398. doi:10.3122/jabfm.2012.03.100270.
PPIs Are Not Responsible for Elevating Cardiovascular Risk in Patients on Clopidogrel-A Systematic Review and Meta-Analysis. Frontiers in Physiology. 2018-11-19, 9: 1550. PMC 6252380 . PMID 30510515. doi:10.3389/fphys.2018.01550.
Pharmacodynamic effect and clinical efficacy of clopidogrel and prasugrel with or without a proton-pump inhibitor: an analysis of two randomised trials. Lancet. September 2009, 374 (9694): 989–997. PMID 19726078. doi:10.1016/S0140-6736(09)61525-7.
Efficacy and Safety of Proton-Pump Inhibitors in High-Risk Cardiovascular Subsets of the COGENT Trial. The American Journal of Medicine. September 2016, 129 (9): 1002–5. PMID 27143321. doi:10.1016/j.amjmed.2016.03.042.

web.archive.org

European Public Assessment Report for Efient (PDF). EMA. 2009 [2020-09-20]. （原始内容存档 (PDF)于2018-03-19）.
Effient (prasugrel hydrochloride) Prescribing Information. FDA. September 2011 [2020-09-20]. （原始内容存档于2017-01-18）.
Efient: Highlights of prescribing information (PDF). [2020-09-20]. （原始内容存档 (PDF)于2019-07-10）.